Katarina N.
- Country
- Sweden
- Department
- Infektionskliniken i Östergötland, Linköpings universitetssjukhus
Research Overview
- Phase II Randomized Study on Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in Shortened Treatment of Drug-Sensitive Pulmonary Tuberculosis
- Efficacy and Safety of Intravenous Immunoglobulin as Add-on to Standard of Care vs Standard of Care Alone in COVID-19 Patients with Severely Impaired B-cell Function
Data & Insights
Has run more than one trial at 1 of 9 partner sites.
Specializations
Infectious Disease Research
The investigator specializes in the treatment of pulmonary tuberculosis, with particular emphasis on exploring innovative therapeutic approaches for drug-sensitive TB cases.
- Treatment optimization strategies
- Antimicrobial therapeutics
- Respiratory infections
Their research focuses on advancing treatment protocols for mild-to-moderate tuberculosis cases.
Treatment Duration Studies
The investigator explores methods to enhance tuberculosis treatment efficiency through the investigation of shortened treatment regimens while maintaining therapeutic effectiveness.
- Treatment duration optimization
- Drug dosing strategies
- Clinical safety assessment
Their work addresses the development of more efficient treatment protocols for pulmonary infections.
Clinical Pharmacology
The investigator conducts research in pharmacokinetics with a focus on antimicrobial medications used in tuberculosis treatment, particularly examining dosing optimization.
- Drug absorption and metabolism
- Dose-response relationships
- Safety profiling
Their expertise extends to the evaluation of medication safety profiles in infectious disease treatment.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.